Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints.

Don’t settle for another dull recap. Deliver PPC QBRs that highlight impact, engage stakeholders, and drive next-quarter strategy.

In January, Gemini agreed to settle a CFTC lawsuit for $5 million. However, the company has since accused the agency's ...

SEC announces plans to host a roundtable to improve cross-border exchange. See why DeepSnitch AI could be the best crypto to ...